We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 4

Figure 4. From: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Event-free survival (EFS) and overall survival by number of delayed intensification (DI) phases. EFS (A) and overall survival (B) by number of DI phases.

Yousif Matloub, et al. Blood. 2011 July 14;118(2):243-251.
2.
Figure 2

Figure 2. From: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Event-free survival (EVS) and overall survival (OS) in randomly assigned patients with B-precursor acute lymphoblastic leukemia.

Yousif Matloub, et al. Blood. 2011 July 14;118(2):243-251.
3.
Figure 3

Figure 3. From: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Event-free survival (EFS) and overall survival (OS) by route of methotrexate (MTX) administration. (A) EFS by route of MTX administration in the interim phases. (B) OS by route of MTX administration in the interim maintenance phases. PO indicates oral.

Yousif Matloub, et al. Blood. 2011 July 14;118(2):243-251.
4.
Figure 5

Figure 5. From: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Five-year cumulative incidence of isolated relapse by route of methotrexate (MTX) administration during the interim maintenance phases. Five-year cumulative incidence of isolated CNS relapse (A), isolated testicular relapse (B), and isolated non-CNS nontesticular extramedullary relapse (C) by route of MTX administration during the interim maintenance phases. PO indicates oral; RHR, relative hazard ratio.

Yousif Matloub, et al. Blood. 2011 July 14;118(2):243-251.
5.
Figure 1

Figure 1. From: Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Protocol schema. OS, included regimen of oral (PO) methotrexate (MTX), mercaptopurine, vincristine, and dexamethasone (during the interim maintenance [IM] phases) and single delayed intensification; OD, included regimen of PO MTX, mercaptopurine, vincristine, and dexamethasone (during the IM phases) and double delayed intensification; IS, included regimen of IV MTX and vincristine (during the IM phases) and single delayed intensification; ID, included regimen of IV MTX and vincristine (during the IM phases) and double delayed intensification. *t(4;11)(q21;q23)(q34;q11), t(9;22), balanced t(1;19)(q23;p13), and hypodiploidy with < 45 chromosomes.

Yousif Matloub, et al. Blood. 2011 July 14;118(2):243-251.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk